Buradasınız

Anasayfa » Content

Medüller Tiroid Kanserlerinde Kemoterapi

Chemotherapy In Medullary Thyroid Carcinoma Cases: Case Report

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Medullary thyroid carcinomas (MTC) constitute 5-10 % of all thyroid cancers. Total thyroidectomy and lymph node dissection are the proposed treatment options, while external radiotherapy, radionuclide treatment and chemotherapy are reported to be useful for palliative purposes. Noncurative chemotherapy regimens are generally used in progressive medullary thyroid carcinoma cases. We tried to evaluate the role of chemotherapy in the treatment of MTK using our chemotherapy results obtained from two different patients, with the diagnosis of sporadic MTK and MEN 2B MTK, to whom we had to use chemotherapy due to the rapid progression of their diseases.
Bookmark/Search this post with
Abstract (Original Language): 
Medüller tiroid kanserleri (MTK) tüm tiroid kanserlerinin %5-10’unu oluşturmaktadır. MTK’lerinin tedavisinde total tiroidektomi ve lenf nodu diseksiyonu önerilmekte, eksternal radyoterapi, radyonüklid tedavi ve kemoterapinin palyatif amaçlı kullanılabileceği bildirilmektedir. Küratif olmayan kemoterapi rejimleri progresif MTK’ler için kullanılmaktadırlar. Hızlı progresyon nedeniyle kemoterapi uyguladığımız biri sporadik, diğeri MEN 2B MTK tanılı iki olgumuzdaki sonuçlarımızla kemoterapinin MTK’deki yerini gözden geçirmeyi amaçladık.
FULL TEXT (PDF): 
PDF icon arastirmax-meduller-tiroid-kanserlerinde-kemoterapi.pdf
  • 3
65-67
  • Turkish

REFERENCES

References: 

1. Marsh DJ, Learoyd DL, Robinson BG. Medullary Thyroid
Carcinoma: Recent advances and management update.
Thyroid 1995; 5(5): 407-24.
2. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH.
Medullary thyroid carcinoma: Clinical characteristics,
treatment, prognostic factors and a comparison of staging
systems. Cancer 2000; 88(5): 1139-48.
3. Greenspan FS. The thyroid gland. In: Greenspan FS, Gardner
DG, eds. Basic and Clinical Endocrinology. 6
th
ed. The
McGraw-Hill Companies, USA, 2001, 201-73.
4. Heshimati HM, Gharib H, van Heerden JA, Sizemore GW.
Advances and contraversies in the diagnosis and management
of medullary thyroid carcinoma. Am J Med 1997, 103(1): 60-
9.
5. Medullary thyroid carcinoma. Thyroid Tumors. In:
Schlumberger M, Pacini F, eds. Editions Nucleon, Paris,1999,
267-300.
6. Stein R, Chen S, Reed l, Richel H, Goldenberg DM.
Combining radioimmunotherapy and chemotherapy for
treatment of medullary thyroid carcinoma: Effectiveness of
dacarbazine. Cancer 2002, 94(1): 51-61.
7. Orlandi F, Caraci P, Berutti A, Puligheddu B, Pivano G,
Dogliotti L, Angeli A. Chemotheraphy with dacarbazine and
5-fluorouracil in advanced medullary thyroid cancer. Ann
Oncol 1994, 5:763-5.
8. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE.
Treatment of advanced medullary thyroid cancer with an
alternative combination of 5 FU-streptozotocin and 5 FU-
dacarbazine. Br J Cancer 1995, 71: 363-5.
9. Nocera M, Baudin E, Pellegriti G, Cailleux AF, MechelanyCorone C, Schulumberger M. Treatment of advanced
medullary thyroid cancer with an alternating combination of
doxorubicin-streptozotocin and 5FU-dacarbazine. Br J Cancer
2000, 83(6): 715-8.
10. Wu LT, Averbuch SD, Ball DW, De Bustros A, Baylin SB,
Mac Guire WP. Treatment of advanced medullary thyroid
cancer with a combination of cyclophosphamide, vincristine
and dacarbazine. Cancer 1994, 73: 432-6.
11. Rugo HS. Cancer. In: Tierney LM, McPhee SJ, Papadakis
MA, eds. Current Medical Diagnosis and Treatment. 39
th
ed.
The McGraw-Hill Companies, USA, 2000, 71-111.

Thank you for copying data from http://www.arastirmax.com